Future clinical studies are warranted to explore the potential utility of CTSS expression as a companion biomarker for guiding anti-PD-L1/PD-1 immunotherapy in CRC and potentially other malignancies. The gene discussed is PDCD1; the disease is colorectal carcinoma.